Eye Cool

Quick links to important sections

Eye Cool

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Eye Cool

Quick Facts Overview

Property Description
Active ingredient Phenylephrine Hydrochloride
Form Ophthalmic solution (Eye drops)
Pharmacological class Adrenergic alpha1-Agonist, Sympathomimetic Agent
General purpose Temporary relief of eye redness (Decongestion)
Origin Synthetic organic compound

Classification and Composition: What Type of Ophthalmic Agent is Eye Cool?

Eye Cool is defined as a sterile ophthalmic solution medication, commonly referred to as eye drops, based on the active pharmaceutical ingredient Phenylephrine Hydrochloride (INN). The medication is formally classified as a sympathomimetic agent that operates as an Adrenergic alpha1-Agonist. This pharmacological profile is characterized by the ability to selectively activate alpha1-adrenergic receptors in the eye. As a synthetic organic compound, Phenylephrine is prepared as a single-ingredient product, dissolved within a purified aqueous base, and designed for targeted topical ophthalmic administration. The product is positioned for fast, temporary relief of minor, non-infectious eye irritation in adult patient groups.

Primary Function: What is the General Purpose of Phenylephrine Hydrochloride?

The primary therapeutic utility of this medication is its function as an Ophthalmic Decongestant, used to alleviate visible eye redness and associated conjunctival congestion. This benefit is achieved through the core physiological action of vasoconstriction, which causes the targeted narrowing of the small blood vessels on the eye’s surface, thereby reducing the appearance of irritation and minor swelling. This decongestant action provides temporary cosmetic relief from redness due to factors like mild environmental irritants or fatigue. The ingredient also possesses the property of inducing mydriasis (pupil enlargement), a function utilized by eye care professionals for clinical diagnostic procedures that require enhanced visibility of the internal ocular structures.

Regulatory References

  1. Phenylephrine Ophthalmic MedlinePlus

What side effects are possible with Eye Cool?

Possible side effects and safety information

The official safety profile of Phenylephrine Hydrochloride ophthalmic solution, the active ingredient in Eye Cool, is separated into Ocular Adverse Reactions (localized effects) and Systemic Adverse Reactions (effects resulting from systemic absorption).

Ocular Adverse Reactions often occur shortly after instillation and include commonly documented events such as eye pain, stinging on instillation, temporary blurred vision, and photophobia (increased sensitivity to light). Regulatory text notes specific time-related patterns, such as rebound miosis occurring approximately one day after use, and transient pigmented aqueous floaters reported in older adults following administration.

Systemic and Serious Adverse Reactions

As a sympathomimetic agent, systemic absorption carries a documented risk of serious Cardiovascular Reactions, particularly with higher concentrations. Official labeling lists clinically significant events, including ventricular arrhythmias, myocardial infarction, syncope, and significant increases in blood pressure (hypertension). These systemic events are classified within official regulatory documents.

Safety Constraints and Special Populations

Specific patient populations are subject to explicit safety constraints. The 10% strength solution is formally contraindicated in patients with pre-existing conditions like hypertension or thyrotoxicosis, and in pediatric patients under one year of age. Caution is also documented regarding use in an inflamed eye or in patients with corneal damage, as this may increase the potential for systemic absorption. Furthermore, an increased risk of an adrenergic response is noted if the solution is used with, or shortly after discontinuing, Monoamine Oxidase Inhibitors (MAOIs). The product is officially designated strictly for topical ophthalmic use and is not for injection.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Phenylephrine Hydrochloride ophthalmic solution focuses on the risk of Systemic Cardiovascular Toxicity resulting from excessive absorption or accidental ingestion.

Documented Overdose Manifestations

System Manifestations
Cardiovascular Rapid rise in blood pressure (Hypertension), Ventricular arrhythmias
Central Nervous System Headache, Anxiety
Gastrointestinal Nausea, Vomiting

Serious or life-threatening outcomes reported in regulatory documents include myocardial infarction, subarachnoid hemorrhage, and fatal reactions following systemic absorption. These severe effects are particularly noted in patients with pre-existing hypertension or those using higher concentrations of the product. An increased risk of systemic toxicity is specifically documented for pediatric patients less than 1 year of age.

Required Emergency Actions

If accidental ingestion or any systemic signs of overdose are suspected, immediate medical attention must be sought. Regulators mandate that patients seek emergency medical attention and contact a Poison Help Line for assistance. Management of systemic toxicity is described as symptomatic and supportive treatment. The use of a rapidly acting alpha-adrenergic blocking agent, such as phentolamine, has been recommended to manage severe pressor effects, and blood pressure monitoring is critical in the management of these cases.

Therapeutic Uses of Eye Cool

What Eye Cool Treats: Main Uses and Benefits

Eye Cool is used to provide temporary relief for a variety of common, non-serious eye discomforts. The product helps manage symptoms associated with minor, temporary irritations of the eye's surface.


Symptom Management and Common Scenarios

This medication is used to provide temporary soothing when eyes feel strained or irritated by environmental factors. Common scenarios for use include exposure to dust, wind, or smoke, or after periods of prolonged reading or screen use. It is used to help reduce the appearance of mild, non-infectious redness, and ease sensations of stinging, burning, or foreign body presence. These applications support the goal of symptomatic relief and functional comfort.


Quick Facts

Eye Cool provides relief for symptoms such as mild eye strain, general fatigue, temporary redness, and irritation caused by external exposure.

Quick Fact: Provides relief for Minor Eye Stinging and Temporary Redness

Eligibility and Restrictions for Use

Who Can and Cannot Use Eye Cool?

Eligibility for using Eye Cool (Phenylephrine Ophthalmic Solution) is defined by regulatory agencies based on pre-existing medical conditions and specific population groups. The medication is contraindicated and must not be used by patients diagnosed with Narrow-Angle Glaucoma, Hypertension (high blood pressure), or Thyrotoxicosis (excessive thyroid hormones), as stated in official labeling.

Population Restrictions and Conditional Use

Population Group Regulatory Status
Pediatric Patients Contraindicated in infants under 1 year (10% strength). Caution is advised for children under 5 years when using higher strengths.
Pregnant Women Use only if clearly needed; safety has not been established in official documents.
Nursing Mothers Caution should be exercised; it is not known if the drug is excreted in human breast milk.
Older Adults Generally approved, but caution is advised due to the potential for increased risk of cardiovascular issues with repeated use of higher strengths.

Conditional use and caution are also advised for adult patients with pre-existing conditions such as Cardiovascular Disease, Diabetes Mellitus, and Hyperthyroidism. The use of this medicine is limited to populations for whom use is officially established and is prohibited in those with listed absolute contraindications.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Eye Cool (Phenylephrine Ophthalmic) primarily through its potential for pharmacodynamic potentiation, where co-administration with certain systemic medications can lead to enhanced adrenergic effects.

Documented Interaction Patterns

The co-administration of Eye Cool with Monoamine Oxidase Inhibitors (MAOIs) is formally documented as a contraindicated combination due to the serious risk of severe adrenergic reactions. This mandatory restriction applies not only during simultaneous use but also for a required separation period of up to three weeks following the discontinuation of the MAOI.

Interactions with other drug classes are classified based on the potential for additive cardiovascular risk. Concomitant use with Tricyclic Antidepressants is documented to potentiate the pressor response, increasing the risk of cardiac arrhythmia. Similarly, co-administration with potent inhalation anesthetic agents, such as Halothane, is documented to increase the risk of ventricular fibrillation by sensitizing the heart muscle.

Furthermore, official labeling notes that combination with certain Anti-hypertensive Agents may result in the reversal of the anti-hypertensive medication's intended action. This systemic interaction risk is specifically documented as increased for patients with pre-existing hypertension or cardiovascular disease, especially when higher concentrations of the ophthalmic solution are administered.

Mechanism of Action

How Eye Cool Works

u1F3AF Selective alpha1-Adrenergic Receptor Agonism

This mechanism involves the drug acting as a direct-acting agonist that selectively engages the alpha1-adrenergic receptors (alpha1-ARs) found on smooth muscle cells. This action mimics the body's sympathetic nervous system signaling, initiating the fundamental physiological cascade for both its primary and secondary effects.


u1F38F Vascular Smooth Muscle Modulation and Vasoconstriction

Activation of the alpha1-ARs on the conjunctival blood vessels triggers an intracellular Ca^2+ signaling cascade . This molecular event forces the vascular smooth muscle to contract, resulting in vasoconstriction (narrowing) of the superficial vessels. This physiological change reduces the localized blood volume, resulting in reduced volume within the surface capillaries.


u1F441uFE0F Secondary Ocular Smooth Muscle Response

The same alpha1-AR activation pathway simultaneously affects the smooth muscle of the iris dilator muscle. Contraction of this muscle is a direct physiological consequence of the drug's mechanism, leading to mydriasis (pupil enlargement). This reflects the anatomical presence of the alpha1-adrenergic system in the anterior eye.

Dosage and Administration Information

How to Use Eye Cool: Administration Guidelines

This section outlines the procedures for administering Eye Cool (Phenylephrine Ophthalmic Solution) for its use as a temporary ocular decongestant.


Administration Scope

Feature Description
Route of Administration Topical Ophthalmic Instillation (directly onto the eye's surface). The solution is strictly designated not for injection.
Dosing Schedule Instill one to two drops (1–2 drops) into the affected eye.
Frequency and Schedule Used only on an as-needed basis (PRN), limited to a maximum of up to four times daily.
Duration Restriction The product is for short-term use only, with limits restricting continuous use to a period of a few days.

Administration Protocol

Special Procedural Conditions

  • The dose is applied via topical ophthalmic instillation into the conjunctival fornix.
  • Immediately after instillation, gentle pressure must be applied to the lacrimal sac (the inner corner of the eye) for a brief period. This measure is intended to limit drainage and potential systemic absorption of the product.

Connection to the overall use protocol

The instructions establish a structured approach defining the Unit Dose and Topical administration route. This protocol is constrained by a maximum daily Frequency and a Short-term duration. The procedural sequence ensures proper localized delivery to the eye's surface.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Action of the Compound Evaluated

Research has evaluated the action of this compound in various models. Studies evaluated the compound's impact on markers relevant to pain perception, which was a focus of some studies. Some investigational devices employ methods such as localized surface cooling to transiently inhibit nerve signaling.


Clinical Evaluation

Clinical research has focused on the compound’s potential impact on pain management across various populations, including those with chronic ocular surface pain (COSP) and post-operative discomfort.

Core Trial Results

One major trial reported that 70% of participants met the pre-defined endpoint of pain level change over the study period. The median duration of participation in the trial was 12 weeks. In other trials, pain levels assessed on a 10-point scale were reported to be significantly lower compared to traditional anesthetic methods.

Specific Condition Research

Studies examined whether there were changes in joint function and mobility when the compound was administered in patients with chronic pain, which was a focus area for research in chronic conditions. In that research, this was primarily conducted in adults aged 45 to 65.


Bioavailability and Formulation

Research evaluated whether the combination was associated with changes in absorption when compared to the active ingredient alone, and changes in the speed of onset of effect were examined. The bioavailability research was conducted using pharmacokinetic models in healthy adult volunteers.


Safety and Tolerability Profile

Studies included analysis of participants with pre-existing kidney conditions. The compound was tested against older treatments in some research. Overall, the evidence provides information regarding the safety profile observed during the trials.

Reported side effects included nausea, fatigue, and headache, which were characterized in the study findings. Long-term use was a subject of investigation in several trials.

Key Studies & References

  1. EyeCool Therapeutics Study (protocol number: ETX4143-A001): Testing a new novel treatment for ocular discomfort
  2. NCT07059754: A Clinical Study to Determine What Effect the EyeCool Treatment Has on the Eye's Surface Anatomy and Inflammation Response After Being Treated for Having Chronic Ocular Surface Pain (COSP)

Frequently Asked Questions (FAQ)

Common questions about Eye Cool (FAQ)

Q: How quickly does Eye Cool usually start working?

Official information indicates that the effect on the pupil, known as mydriasis or pupil dilation, typically begins within 15 minutes of administration, reaching maximum effect between 20 and 90 minutes after the drops are applied. This provides a general expectation of the medication's onset.

Q: How does Eye Cool differ from traditional dry eye drops?

Eye Cool is classified as a vasoconstrictor and mydriatic, meaning it works by narrowing blood vessels on the eye's surface and dilating the pupil. This is different from traditional dry eye drops, which are typically used primarily to lubricate the eye surface or replace natural tears.

Q: Are there different strengths of Eye Cool available?

According to official dosage form information, Phenylephrine ophthalmic solution is commonly available in different concentrations, including lower strengths for decongestion and higher strengths, such as the 2.5% and 10% solutions, often used for diagnostic purposes. Official documents emphasize that different strengths are used for different purposes.

Q: What happens if you use Eye Cool more often than described on the packaging?

Regulatory documents caution that exceeding the recommended dosage or frequency may increase the risk of the medicine being absorbed into the body, which is called systemic absorption. This can lead to potentially serious cardiovascular adverse reactions, such as significant increases in blood pressure (hypertension) or heart rhythm changes.

Q: Can Eye Cool cause drowsiness or affect driving ability?

Official labeling lists ocular adverse reactions like temporary blurred vision and photophobia (increased light sensitivity). Use of this medication may interfere with activities like driving or operating machinery. Regulatory information suggests delaying these activities until visual acuity returns to normal.

Q: Does Eye Cool affect the results of an eye exam?

The medication is described as causing pupil dilation (mydriasis), which is the enlarging of the pupil. This effect is used in clinical procedures to help eye care professionals better examine the internal structures of the eye. Therefore, the medication’s action is part of the diagnostic process.

Q: Why do official documents emphasize that Eye Cool is not a cure?

The medication is approved for temporary relief of eye redness or for diagnostic purposes. Because it provides relief by constricting blood vessels rather than treating the underlying cause, it is only intended for short-term use and should not be viewed as a permanent cure for eye conditions.

Q: What are the main components of Eye Cool besides the active ingredient?

Official product information notes that the solution contains the active ingredient (Phenylephrine) in an aqueous base (purified water). It commonly includes sodium phosphate buffers to balance the solution and may contain a preservative such as Benzalkonium Chloride to maintain sterility in multi-dose bottles.

Q: Why does the packaging for Eye Cool include a specific warning about a certain medical condition?

Warnings are included because the medication has a documented risk of serious cardiovascular reactions if absorbed systemically, particularly when higher concentrations are used. This risk includes significant increases in blood pressure. Therefore, the official labeling includes contraindications for people with pre-existing conditions like hypertension or thyrotoxicosis.

Q: Can Eye Cool be bought without a prescription?

The active ingredient, Phenylephrine, is included in the FDA's Over-the-Counter (OTC) monograph for ocular decongestion when used in low concentrations, such as 0.08% to 0.2%. However, higher strengths, like the 2.5% and 10% solutions, are typically regulated as prescription-only products, primarily for use in diagnostic procedures.

Q: How long do the effects of Eye Cool typically last?

For the purpose of pupil dilation during diagnostic exams, the official pharmacodynamic information indicates the effect typically lasts between 3 to 8 hours. If the pupil remains dilated for significantly longer than this timeframe, regulatory information suggests checking with a healthcare professional.

Q: Is it possible to have an allergic reaction to Eye Cool?

Official labeling lists known hypersensitivity to any component of the solution as a formal contraindication, which means its use is restricted if this is a known risk. Like most medications, the adverse reaction profile may include the potential for localized issues such as conjunctival sensitization (an allergic response on the eye surface).

Q: Are there any specific foods or drinks that interact with Eye Cool?

The official drug label does not list specific food-drug interactions. Due to Phenylephrine’s classification as a stimulant, high consumption of caffeine-containing foods or drinks may result in additive side effects like nervousness or rapid heartbeat.

Q: Is Eye Cool considered a controlled substance?

No, Phenylephrine ophthalmic solution is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA). This means it is not subject to the scheduling and regulatory controls applied to narcotics and certain other high-potential medications.

Q: How long after using Eye Cool can I safely drive?

Because the medication can cause temporary blurred vision and photophobia (light sensitivity), activities requiring clear sight, such as driving, should be delayed. Regulatory information suggests delaying these activities until visual acuity returns to normal and light sensitivity has subsided.

Q: Can Eye Cool be used by people with a history of eye surgery?

Official warnings note that use of Phenylephrine ophthalmic solution may present an increased risk in the setting of recent eye surgery or eye injury. This caution is due to the potential for increased systemic absorption of the medication through a compromised ocular surface.

Q: Is it normal to see some mild redness after using Eye Cool?

After the intended vasoconstriction (blood vessel narrowing) effect wears off, the adverse event profile notes the possibility of reactive hyperemia. This is a form of rebound redness that may temporarily occur on the surface of the eye following the cessation of the drug's effect.

Q: Are there any known interactions between Eye Cool and herbal supplements?

Official labeling does not list specific interactions with herbal supplements. However, it is noted that some herbal supplements may contain stimulants or caffeine that could result in additive effects with Phenylephrine, potentially increasing the risk of systemic side effects like nervousness or cardiac effects.

Q: What does the patient leaflet say about stopping the use of Eye Cool?

Official patient information directs that if a healthcare professional recommends discontinuing the eye drops, or if they have expired, the unused medication should be returned to a pharmacist for appropriate pharmaceutical waste disposal. This is to prevent improper disposal via household waste or waterways.

How should Eye Cool be stored and disposed of?

How to Store and Dispose of Eye Cool?

The storage and disposal of Eye Cool (Phenylephrine Ophthalmic Solution) must follow regulatory requirements to maintain its stability and sterility.


Official Storage Conditions

The product must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). Do not freeze the solution. It must be kept in the original container, tightly closed, and protected from light. To prevent contamination, do not touch the dropper tip to any surface.

Stability and Disposal Rules

Single-use containers must be discarded immediately after use. Multi-dose bottles may need to be discarded within a specific period, such as 28 days after first opening, according to the labeled stability requirements. The medicine must be kept out of the sight and reach of children. Unused or expired product should not be disposed of via wastewater or household waste; dispose of it through an appropriate pharmaceutical waste collection scheme.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Eye Cool found in:

A-Z Index: